Following people with sphingosine phosphate lyase insufficiency syndrome over time
Observes how sphingosine phosphate lyase insufficiency syndrome develops and affects quality of life and survival.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
- Status
- Recruiting
- People taking part
- 28 people, planned
- Started
- 22 Apr 2025
- Expected to end
- 31 Dec 2030
- Type of study
- Observational, 3 groups
- Record updated
- 4 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for living or deceased people with SPLIS, a rare inherited metabolic disease, confirmed by genetic testing. Parents of patients and people of similar age and sex may join as controls.
- Sex
- All sexes can join.
- Disease stage
- Any form of SPLIS. People can join whether or not they have active disease, and whether or not they take vitamin B6, are on dialysis or have had a kidney transplant.
- Earlier treatment
- People who used an investigational (trial) drug in the last 30 days cannot join. Off-label use of medicines is allowed.
- Biomarker or test result
- Changes in both copies of the SGPL1 gene. This means disease-causing or likely disease-causing variants, or other changes plus a SPLIS feature, lab signs of lost S1P lyase function, or a sibling with SPLIS.
Main reasons for not taking part
- Use of an investigational drug now or in the last 30 days (patients or their parents)
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Potential subjects fulfilling the following criteria will be eligible to participate in this study:
- Living or deceased patients diagnosed with SPLIS based on; harbor biallelic pathogenic variant (PV) or likely PV (LPV) in the SGPL1 gene, regardless of phenotype OR; harbor nucleotide changes in both SGPL1 alleles, regardless of variant classification, if they also have one of the following: b1) exhibit at least 1 phenotypic feature of SPLIS (nephrosis, endocrine defect, ichthyosis, neuropathy, male gonadal dysgenesis, lymphopenia) b2) have evidence from biochemical or molecular data (such as enzyme expression or activity in skin fibroblasts) that indicate a possible loss of function in the S1P lyase (SPL) protein b3) are a sibling of a subject with nucleotide changes in both alleles of SGPL1 and at least 1 phenotypic feature of SPLIS
- Informed consent and (if appropriate) assent for living subjects. For deceased subjects, the Principal Investigator (PI) will be responsible for ensuring that all requirements have been met in regard to the relevant local laws and regulations. Parents of participating SPLIS patients may be included as controls
Who cannot take part
- Subjects with SPLIS (or their parents) who are currently using or have a history of using an investigational agent in the last 30 days with the exception of off-label use of medications will be excluded from the study
Other criteria
- All identified patients with SPLIS diagnosed by genetic criteria are eligible for enrollment in this study, regardless of baseline demographic, biochemical or metabolic features and regardless of interventions such as vitamin B6 supplementation, dialysis or kidney transplantation at time of enrollment. This study may include siblings of index SPLIS cases if the sibling has been genetically confirmed to have SPLIS, regardless of whether they have active disease at the time of enrollment. Data from deceased SPLIS patients will also be collected
Where in United States
- University of California San FranciscoSan Francisco, United StatesContact: Julie D Saba, MD, PhDTaking people
About the trial
What the trial wants to find out
This is a prospective longitudinal natural history study with a retrospective cross-sectional arm aimed at determining the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS), a recently recognized inborn error of metabolism. The central hypothesis is that age of onset, other disease features, and disease biomarkers will be predictive of quality of life (QOL) and survival in SPLIS patients.
The 3 groups in the trial
- Individuals with sphingosine phosphate lyase insufficiency syndrome
Individuals diagnosed with sphingosine phosphate lyase insufficiency syndrome based on genetic testing that confirms bi-allelic pathogenic variants in the SGPL1 gene
- Parents of individuals with sphingosine phosphate lyase insufficiency syndrome
Parents of individuals diagnosed with sphingosine phosphate lyase insufficiency syndrome based on genetic testing that confirms bi-allelic pathogenic variants in the SGPL1 gene
- age and gender-matched controls
The investigators will attempt to collect biological specimens from individuals closely matched to SPLIS patient cohort by age and gender. This group may include siblings, cousins, and unrelated healthy children and adults.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Natural History and Phenotypic Spectrum of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
- Plain-language title
- Following people with sphingosine phosphate lyase insufficiency syndrome over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 4 August 2026